Novel scaffolds for modulation of TRPV1 identified with pharmacophore modeling and virtual screening

Future Med Chem. 2015;7(3):243-56. doi: 10.4155/fmc.14.168.

Abstract

Aim: The transient receptor potential vanilloid type 1 (TRPV1) is responsible for pain perception in the peripheral nervous system (PNS). TRPV1 is thus considered a versatile target for development of non-opioid analgesics.

Results: Pharmacophore-based clustering of a publicly available data set of TRPV1 antagonists revealed a set of models, which were validated with data sets of inactive compounds, decoys and known drug candidates. The top ranked pharmacophore models were subsequently used for virtual screening. Based on a unique in-house protocol, a set of compounds was selected and biologically tested for modulation of TRPV1 in a voltage-clamp model.

Conclusion: Pharmacophore models extracted from large public data sets are a valuable source for identification of novel scaffolds for TRPV1 receptor modulation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Algorithms
  • Analgesics, Non-Narcotic / pharmacology*
  • Drug Evaluation, Preclinical
  • Humans
  • Ligands
  • Models, Molecular
  • Peripheral Nervous System / drug effects
  • Peripheral Nervous System / metabolism
  • TRPV Cation Channels / antagonists & inhibitors*
  • TRPV Cation Channels / metabolism

Substances

  • Analgesics, Non-Narcotic
  • Ligands
  • TRPV Cation Channels
  • TRPV1 protein, human